In January 2006, FDA issued a final rule which specified that most pharmaceutical products (including biologics) produced for use in Phase I clinical trial studies were exempted from complying with GMP requirements, as defined in 21 CFR Part 211 under 21 CFR 210.2(c). Section 501(a)(2)(B) of the FD&C Act requires drugs, including IND products, to comply with cGMPs or if they are not manufactured in compliance with cGMPs, they are deemed adulterated. Based on this statutory requirement for manufacturers to follow GMPs, FDA issued cGMP regulations for drug and biological products in the Code of Federal Regulations (in 21 CFR parts 210 and 211). There are certain requirements in 21 CFR Part 211 that are directed at the commercial manufacture of products typically characterized by large, repetitive, commercial batch production and requirements as a result, are not appropriate to the manufacture of most investigational drugs used for phase I clinical trials. Based on these issues, application of cGMPs to Phase I investigational drug products was exempted from 21 CFR 211. However, based on statutory requirements as given in Section 505(i) of the FD&C Act, FDA issued regulations governing IND products in order to protect human subjects enrolled in clinical trials, specifically with regards to the chemistry, manufacturing and controls data submitted as part of IND applications for drugs or biological products.
Subsequent to FDAs final rule of January 2006, FDA released the Guidance for Industry, "INDs- Approaches to Complying with CGMP During Phase I". This document describes the CMC data necessary for inclusion in the IND. FDA reviews the IND to determine whether phase I investigational drugs to be used in the clinical trial to permit the trial to proceed, which is partially dependent on whether the product has the identity, strength, quality and purity and purported effect described in the IND application. FDA can chose to place the IND on clinical hold or could terminate the IND based on their review. If an IND is placed on clinical hold, the hold may be removed if the sponsor addresses the deficiencies, but clinical trials may not progress until the clinical hold is removed.
In July 2008, FDA issued an additional Guidance for Industry, "CGMP for Phase I Investigational Drugs", in order to provide guidance to sponsors regarding meeting GMPs appropriate for Phase I investigational drug products. In this seminar, the attendees will gain a complete understanding of all current good manufacturing practices that are applicable to the manufacture of Phase I investigational drug product, in addition to understanding which products were exempt and which were not. The attendees will gain an understanding of CMC data necessary for the preparation of an Investigational New Drug application, and have an understanding of the requirements of the document and therefore avoid clinical holds or termination of the IND. Additionally, based on the products that were exempted from GMPs as defined in 21 CFR part 211, several guidance documents were created to provide guidance regarding the content and format of the CMC information necessary for inclusion in the IND for the following products: for Phase I, studies of drugs, including well-characterized, therapeutic, biotechnology-derived products, for somatic cellular therapy and for human gene therapy INDs.
Why should you attend:
FDAs guidance document "Good Manufacturing Practice for Phase I Investigational Drug Products" applies to correct GMP requirements to drug products made for the purpose of using an investigational drug product on human subjects for the first time, during conduct of Phase I clinical trials, which can begin if your IND is not put on clinical hold in 30 days after receipt by the FDA. If they review your IND and the appropriate information is not available to ensure FDA of the quality of the product, the IND will be placed on clinical hold, preventing your clinical program from going forward. The necessary content of the IND will not be discussed in this webinar, but the specific GMPs for Phase I Investigational drugs will be understood by attendees, therefore allowing the applicant to apply only those GMPs which are applicable to the drug product at this stage of development, instead of trying to apply GMPs, as defined in 21 CFR Part 211, to Phase I Investigational drug products, which often leads to frustration and even errors, as the CFR definition was meant for commercial batches, which are large and repetitive, as well as different in other ways, making the application of some of the GMPs for finished drug products impossible.
Who will benefit:
- Quality Associates or Specialists
- Regulatory Management or Regulatory Specialists
- Compliance professionals
- Quality Auditors
- Validation Engineers
- R & D Scientists- chemists, geneticists, biochemistry specialists, formulation chemistry
- Laboratory Personnel
- Senior Quality Managers, Quality VPs
Agenda:Day 1 Schedule
Lecture 1(90 Mins):
30 Minutes: brief overview of the objectives of the seminar, brief introduction of attendees, including their functions, type of products that they are working on (if applicable), and the function(s) they serve.
60 Minutes: an explanation of the statutory requirements, the changes that precipitated the products being exempt and the specific products exempt and those that were not exempt will be discussed.
Lecture 2(90 Mins):
Brief discussion of the product lifecycle, including when regulatory filings, such as the IND and NDA (or the equivalent, depending on region) are filed, description of differences in chemically-synthesized drug and biologic products and biotech products will be briefly discussed. Brief discussion of the Pharmaceutical Quality System, as per ICH Q10 (and the companion documents, ICH Q8, pharmaceutical development and ICH Q9, quality risk management, will be introduced.
Lecture 3(90 Mins):
15-30 Minutes: brief discussion of GMPs for APIs, specifically the information that addresses GMPs for products in clinical trials, ICH Q7. GMPs for phase I investigational drug products will be dsicussed, including guidance for complying with the statute, discussion of having appropriate QC procedures in effect during product development to ensure the quality and safety of the investigational drugs are maintained, as well as emphasis on following appropriate GMPs, as both of these actions will facilitate the manufacture of equivalent of comparable IND product for future clinical trials. Several different resources/technologies are suggested to facilitate conformance with cGMPs and to streamline product development.
Lecture 4(90 Mins):
Additional review of GMPs for phase I investigational drug products, including personnnel, QC function, facility and equipment, control of components, and containers and closures, manufacturing and records, laboratory controls, including testing and stabilit, packaging, labeling and distributing and recordkeeping will be addressed. If we do not get through all of the information just mentioned in this time period, the dicussion will continue the following day, along with the remaining content that needs to be understood for implementing GMPs for Phase I Products.
Day 2 Schedule
Lecture 1(90 Mins):
Continued discussion of GMPs for Phase I Investigational drug products, including content from previous day and the special manufacturing situations, such as multi-product facilities.
Lecture 2(90 Mins):
Continued discussion of GMPs for Phase I Investigational drug products to include considerations and adventitious agent control will be addressed in regards to biological and biotechnological products. Gene therapy and cellular therapy products will be addressed, as well as sterile products/aseptically processed products. The remaining time will introduce "INDs - Approaches to complying with CGMP during Phase I".
Lecture 3(90 Mins):
The IND Regulation(21 CFR 312.23(a)(7)(i)) will be reviewed, including the "sufficient CMC information to ensure the proper identification, quality, purity, and strength of the investigational drug." Each item (identification, quality, purity, and strength of the investigational drug) will be reviewed, including meaning of each, some of the requirements, such as strength and assays for drug substance and drug product, validation requirements of each, blend uniformity, uniformity of dosage units, container/closure, stability, etc. If additional time is left, will start review of CMC regulatory requirements.
Lecture 4(90 Mins):
The CMC regulatory requirements, including requirements for drug substance (APIs) and drug products. Potential safety concerns for an investigational drug product (and its' drug substance) will be discussed in order to help attendees avoid safety issues and clinical holds. Other potential hold issues will be addressed, including impurities, expiration dating, etc. will be addressed. The ICH guidance documents specific for identity, stability, etc. will be provided to the attendees. Questions will be accepted throughout the seminar, but any questions that the attendees have and discussions are encouraged to ensure that all attendees have any questions answered.
Location: Salt Lake City, UT Date: May 10th & 11th, 2018 and Time: 9:00 AM to 6:00 PM
Venue: Hilton Garden Inn Salt Lake City Airport 4975 Wiley Post Way, Salt Lake City, Utah, 84116, USA
Sponsorship Program benefits for “Phase I Investigational Drug Products | USA Seminar 2018” seminar
For More Information- https://www.globalcompliancepanel.com/control/sponsorship
Contact us today!
NetZealous LLC DBA GlobalCompliancePanel
Toll free: +1-800-447-9407
Registration Link - https://www.globalcompliancepanel.com/control/globalseminars/~product_id=901552SEMINAR?SEO
Follow us on LinkedIn: https://www.linkedin.com/company/globalcompliancepanel/
Like us our Facebook page: https://www.facebook.com/TrainingsAtGlobalCompliancePanel/
Follow us on Twitter: https://twitter.com/GCPanel
President/CEO, Cooke Consulting Inc.
Stephanie Cooke, is the President/CEO of Cooke Consulting, Inc. Stephanie uses her roughly 20 years of experience to provide global consulting services in various areas of Regulatory Affairs, Quality Assurance and validation for pharmaceutical, biological/biotech products, medical device, combination drug/device and nutraceutical firms. Her broad-based experience includes preparation of regulatory dossiers for human and animal pharmaceutical (chemical entities and biologically-based drugs), biotech products, drug/device combination products and medical devices in all stages of development (INDs, NDAs, BLAs, post-marketing supplements such as CBEs, Prior approval supplements, orphan drug designation and related submissions, 510ks, PMAs and HDEs).
Price: $1,295.00 (Seminar Fee for One Delegate)
Register for 5 attendees Price: $3,885.00 $6,475.00 You Save: $2,590.00 (40%)*
Register for 10 attendees Price: $7,122.00 $12,950.00 You Save: $5,828.00 (45%)*
Register now and save $200. (Early Bird)Until March 31, Early Bird Price: $1,295.00 From April 01 to May 7, Regular Price: $1,495.00
|Thu, Fri||09:00 AM — 06:00 PM|
|No. of Days:||2|
|No. of Participants:||100|
GlobalCompliancePanel is a training source that delivers diverse, high quality regulatory & compliance trainings. These trainings are simple while being relevant and cost-effective while being convenient.
GlobalCompliancePanel imparts knowledge of best practices across a broad range of user-friendly mediums such as webinars, seminars, conferences and tailored, individualized consulting. These help organizations and professionals implement compliance programs that meet regulatory demands and put business processes in place.GlobalCompliancePanel focuses primarily on providing extensive and quality training in these core areas and anything related to them:
- Risk Management
- Regulatory Compliances
- Corporate Governance
- Quality Management
Through the mediums by which we offer trainings, namely webinars, seminars, conferences and consulting, we bring together the regulators or experts on regulation on the one hand, with the community that needs to learn or be aware of those regulations, on the other.
Professionals who undergo trainings from GlobalCompliancePanel exhibit a vastly improved quality of life in which there is increased productivity and professional growth. In the 10 years for which it has been in the professional trainings industry; GlobalCompliancePanel has developed a rich legacy of courses. It boasts an amazingly large repertoire of 5000 courses, which consist of over 2000 in-person seminars. ...